Is trastuzumab every three weeks ready for prime time?

Journal of Clinical Oncology

Volumn 21, Issue 21, 2003, Pages 3900-3901

  Cobleigh, Melody ^a   Frame, David ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; PRIORITY JOURNAL; SIDE EFFECT; BLOOD; BREAST TUMOR; DRUG ADMINISTRATION; FEMALE; METASTASIS; NOTE; PATHOLOGY; PHASE 2 CLINICAL TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; NEOPLASM METASTASIS;

EID: 0642281449     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.984     Document Type: Editorial

References (10)

1. Leyland-Jones B, Gelmon K, Ayoub J-P, et al: Pharmacokinetics, safety, and efficacy of trastuzumab administered every 3 weeks in combination with paclitaxel. J Clin Oncol 21:3965-3971, 2003
2. Gelmon K, Arnold A, Verma S, et al: Pharmacokinetics (PK) and safety of trastuzumab (Herceptin) when administered every three weeks to women with metastatic breast cancer. Proc Am Soc Clin Oncol 20:69a, 2001 (abstr 271)
3. Harris K, Washington CB, Lieberman G, et al: A population pharmacokinetic (PK) model for trastuzumab (Herceptin) and implications for clinical dosing. Proc Am Soc Clin Oncol 21:123a, 2002 (abstr 488)
4. Cobleigh MA, Vogel CL, Robert NJ, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
5. Carbonell Castellon X, Castaneda-Soto N, Clemens M, et al: Efficacy and safety of 3-weekly herceptin (H) monotherapy in women with HER2-positive metastatic breast cancer (MBC): preliminary data from a phase II study. Proc Am Soc Clin Oncol 20:19a, 2002 (abstr 73)
6. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
7. Seidman A, Hudis C, Pierri MK, et al: Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215-1221, 2002
8. Baselga J, Tripathy D, Mendelsohn J, et al: Phase II study of weekly intravenous recombinant humanized anti- p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996
9. Pegram MD, Lipton A, Hayes DF, et al: Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16:2659-2671, 1998
10. Vogel C, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002